FDA Updates HIV Drug Label to Include Dosing for Pregnant Patients
The FDA updated the labeling for rilipivirine (Edurant) for the treatment of HIV-positive pregnant patients who were on stable treatment prior to conception and who are virologically suppressed.
Today, the FDA updated the labeling for rilipivirine (Edurant) for the treatment of HIV-positive pregnant patients who were on stable treatment prior to conception and who are virologically suppressed, according to an agency update.
The label recommends that these patients take one 25-mg tablet once per day with a meal. The FDA noted that lower exposures of rilipivirine were observed during pregnancy, meaning that viral load should be monitored closely.
The update also includes clinical considerations dealing with dose adjustments that are necessary during pregnancy and post-partum.
For more information, visit SpecialtyPharmacyTimes.com.
